{
    "2019-07-17": [
        [
            {
                "time": "",
                "original_text": "【中信建投医药】科创板系列研究之成都先导：DNA 编码化合物库为核心的研发型特色CRO",
                "features": {
                    "keywords": [
                        "成都先导",
                        "科创板",
                        "DNA编码化合物库",
                        "研发型CRO"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "成都先导九成营收来自海外 坏账政策较可比公司宽松",
                "features": {
                    "keywords": [
                        "成都先导",
                        "海外营收",
                        "坏账政策"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}